David Hong, MD
Allergy & Immunology · Chestnut Hill, MANPI 1316079908
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $27,687 of the $35,047 with a category attached, or 79.0%. Eli Lilly accounts for 79.0% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $27,687 and has fallen 99.5% since, to $126 in 2025.
Across 11 payments — averaging $3186.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$28K
- Novartis$6K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Sanofi-aventis U.S. LLC$95
- AstraZeneca$77
- Johnson & Johnson$31
What the payments were for
- Consulting fees$7,15820%
- Speaking & faculty fees$27,68779%
- Food & beverage$1080%
- Education$950%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 5 | $27,687 |
| Novartis | 2 | $5,995 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,163 |
| Sanofi-aventis U.S. LLC | 1 | $95 |
| AstraZeneca | 1 | $77 |
| Johnson & Johnson | 1 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,047 in reported general payments places this provider in the 85th percentile of 114 allergy & immunology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 14 | $386,484 |
| XolairOmalizumab | 44 | $139,708 |
| NucalaMepolizumab | 37 | $135,459 |
| Dupixent SyringeDupilumab | 13 | $43,726 |
| Spiriva RespimatTiotropium Bromide | 15 | $9,143 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $5,288 |
| Epinephrine | 41 | $5,136 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $4,699 |
| Fluticasone Propionate HfaFluticasone Propionate | 11 | $3,752 |
| Wixela InhubFluticasone Propion/Salmeterol | 12 | $1,999 |
| Azelastine Hcl | 28 | $1,244 |
| Ipratropium Bromide | 22 | $800 |
| Ventolin HfaAlbuterol Sulfate | 13 | $701 |
| Fluticasone Propionate | 31 | $678 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 27 | $601 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $1,163 | $386,48414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 114 allergy & immunology providers in Massachusetts.
Other allergy & immunology in Chestnut Hill
- Joshua BoyceChestnut Hill$22K
- Trisha RayChestnut Hill$5K
- Nora BarrettChestnut Hill$3K
- Daniel SteinbergChestnut Hill$2K
- Wanda PhipatanakulBoston$679K
- Jonathan BayukNorthampton$420K
- Kathleen BuchheitBoston$224K
- Francisco BonillaLeominster$188K
- Aleena BanerjiBoston$133K
- Margo StevensonSturbridge$98K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.